PULMONX CORP

NASDAQ: LUNG (Pulmonx Corporation)

最近更新时间: 29分钟之前

2.74

0.05 (1.86%)

前收盘价格 2.69
成交量 503,210
价格/销量 (P/S) 1.32
股市价格/股市净资产 (P/B) 3.48
52周波幅
1.13 (-58%) — 3.25 (18%)
营业毛利率 -65.27%
营业利益率 (TTM) -64.61%
稀释每股收益 (EPS TTM) -1.44
季度收入增长率 (YOY) 19.50%
总债务/股东权益 (D/E MRQ) 73.32%
流动比率 (MRQ) 4.97
营业现金流 (OCF TTM) -32.96 M
杠杆自由现金流 (LFCF TTM) -13.19 M
资产报酬率 (ROA TTM) -22.20%
股东权益报酬率 (ROE TTM) -60.68%

AIStockmoo 评分

0.1
资本回报低于资本成本。资本回报下降。 参考
负债低。盈利能力弱。短期流动性充足。现金流为负。 参考
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
持仓估值 参考 NA
风险溢价 参考 NA
市场估值 参考 NA
过去一年没有明确趋势。股价略低于52周高点。 参考
上升趋势:股价位于均线之上,均线向上。股价接近均线。上涨日成交量较大。 参考
来自我们对走势图的 AI 技术分析。 参考 NA
K线形态 参考 NA
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻大多正面。 参考
持仓情绪 参考 NA
机构在最新13F申报中净+3.45%的股份:45家增持,67家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化-19.3%,回补天数1天(FINRA)。 参考
内部交易活动 参考 NA
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向不一,评分因此减弱。
高于中期趋势线。 参考
股价高于其52周平均水平。5年来下跌。 参考
短、中、长期趋势均向上。短期动能上升。 参考
股价接近支撑位。支撑与阻力水平趋升。 参考
最终评分 0.14
全部展开

市场趋势

短期 中期
行业 Medical Devices (US) 混合的 混合的
Medical Devices (全球的) 混合的 混合的
股票 Pulmonx Corporation 混合的 看涨

相关股票

股票 市值 DY P/E(TTM) P/B 评分
LUNG - - - 3.48 0.1
SMLR 368 M - 7.48 - -0.4
BSGM 169 M - - 36.58 -0.1
IINN 19 M - - 13.64 -0.4
PTHL 15 M - - 2.19 0.0
RSLS 4 M - 0.019 30.42 -0.8

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

部门 Healthcare
行业 Medical Devices
投资方式 Small Value
内部持股比例 4.40%
机构持股比例 90.83%

所有权

姓名 日期 持有股份
Primecap Management Co/Ca/ 30 Sep 2026 4,408,431
Soleus Capital Management, L.P. 30 Sep 2026 3,088,323
Almitas Capital Llc 30 Sep 2026 1,080,038
Parkman Healthcare Partners Llc 30 Sep 2026 853,986
Braidwell Lp 30 Sep 2026 752,541
D. E. Shaw & Co., Inc. 30 Sep 2026 740,868
Marshall Wace, Llp 30 Sep 2026 660,466
Geode Capital Management, Llc 30 Sep 2026 536,268
Renaissance Technologies Llc 30 Sep 2026 530,336
Acadian Asset Management Llc 30 Sep 2026 522,987

该时间范围内无数据。

机构

机构持股比例: 67.43%

持仓变动 机构数 股数
增持 45 4,687,719
减持 67 3,808,268
新建仓 17 1,217,235
清仓 24 578,840

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 787,512 1.0
15 Oct 2026 698,644 2.5
30 Sep 2026 802,733 3.2
15 Sep 2026 847,842 2.5
31 Aug 2026 976,237 2.6
14 Aug 2026 1,066,574 1.2

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

2 正面 0 负面 1 中性
日期 类型 细节
18 Nov 2026 Yahoo Finance Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside discussion at the Piper Sandler 38th Annual Healthcare…
17 Nov 2026 Yahoo Finance Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System
Study demonstrates potential to enable Zephyr® Valve treatment for selected severe COPD/emphysema patients previously ineligible due to collateral ventilationREDWOOD CITY, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in…
08 Nov 2026 Yahoo Finance Pulmonx: 3 Key Takeaways for Long-Term Investors
Gross margins above 75% and a narrowing path to cash flow breakeven give the turnaround real financial teeth.
30 Oct 2026 Yahoo Finance All You Need to Know About Pulmonx (LUNG) Rating Upgrade to Buy
Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
28 Oct 2026 Yahoo Finance Pulmonx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity…
27 Oct 2026 Yahoo Finance Pulmonx (LUNG) Q3 2026 Earnings Call Transcript
Revenue returned to growth while losses narrowed significantly on cost discipline.
27 Oct 2026 Yahoo Finance What Pulmonx (LUNG) Said on Its Q3 Earnings Call
Pulmonx (NASDAQ:LUNG) reported third-quarter revenue growth and a narrower loss as the company cited progress in rebuilding its U.S. sales organization, tightening expenses and advancing clinical programs intended to expand its market. Total worldwide revenue for the quarter ended Sept. 30 was $22…
27 Oct 2026 Yahoo Finance Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
Pulmonx (LUNG) delivered earnings and revenue surprises of +26.92% and +3.75%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
27 Oct 2026 Yahoo Finance Pulmonx Reports Third Quarter 2026 Financial Results
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2026 ended September 30, 2026. Recent Highlights…
13 Oct 2026 Yahoo Finance Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026
REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday…
03 Sep 2026 Yahoo Finance Pulmonx Shares Fall Following Recent Gains
Pulmonx (NASDAQ:LUNG) shares fell 10. 1% to $2…
01 Sep 2026 Yahoo Finance Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025…
26 Aug 2026 Yahoo Finance Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
显示更多

技术形态 中期

趋势排列
斜率
入场位置
成交量
上升趋势:股价位于均线之上,均线向上。股价接近均线。上涨日成交量较大。
最近支撑: 2.36 – 2.66 · 强 · 多次测试,可能失守
最近阻力: 3.10 – 3.32 · 强

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票